Citibank: Target price of HK$8 for the “buy” rating for Ali Health (00241)

Zhitong Finance02:19

Bank of America Securities: Maintaining Ali Health's “Buy” Rating, Target Price HK$4.5

Zhitong Finance21:26

Bank Ratings｜Bank of America: Maintaining Alibaba Health's “Buy” Rating Annual Results Outperform Expectations

Gelonghui Finance21:25

China Resources Healthcare (01515.HK): Innovate operation and management, expand business integration with internal and external resources to increase performance

東北證券May 6 11:00

Big Bank Rating | Damo: Raising the target price of Chinese medicines to HK$5.4, attracting valuation

Gelonghui FinanceApr 25 21:50

Sansheng Pharmaceutical (01530.HK): Approval of ITP indications for children in Terbi Australia is expected to support continued income growth

太平洋證券Apr 11 11:00

China Resources Pharmaceuticals (03320.HK): Steady growth in performance, high-quality epitaxial expansion to expand new growth points

天風證券Apr 10 05:46

Research Report: Zheshang Securities: Maintaining Fosun Pharmaceuticals' “Buy” Rating, Optimistic About the Company's International Implementation

Gelonghui FinanceApr 9 04:33

Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain

Zhitong FinanceApr 8 21:01

Big Bank Rating | Dahua Jixian: Lowering Ali Health's Target Price to HK$4 to Maintain “Buy” Rating

Gelonghui FinanceApr 7 21:22

Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

TipRanksApr 5 04:40

Hanson Pharmaceuticals (3692.HK): Independent R&D and BD cooperation drive steady growth in the company's performance

華興證券Apr 2 11:00

China Resources Pharmaceutical (03320.HK): Performance meets expectations and further deepens marketing system transformation

中金公司Apr 1 11:00

Xianjian Technology (01302.HK): Increased R&D investment, looking forward to continuous gains in the innovation pipeline

中金公司Mar 30 11:00

Ali Health (0241.HK) 2HFY24 Performance Forecast: High base effect puts pressure on revenue growth in the short term

華泰證券Mar 29 08:01

Bank Rating | Citibank: Raising Hanson Pharmaceuticals Target Price to HK$28 to Maintain “Buy” Rating

Gelonghui FinanceMar 29 03:48

Hanson Pharmaceuticals (3692.HK): Innovative drugs will lead steady revenue growth

中泰國際Mar 28 06:36

Citibank: Maintaining Hanson Pharmaceuticals (03692)'s “Buy” Rating and Raising the Target Price to HK$28

Zhitong FinanceMar 28 03:54

Tong Ren Tang Technology (01666.HK): Revenue is in line with expectations, increased layout of core products

中金公司Mar 28 03:46

CICC: Maintaining China Resources Healthcare's (01515) “Outperform the Industry” Rating Target Price of HK$5.6

Zhitong FinanceMar 28 00:50